Zai Lab Limited
ZLABDrugs in Pipeline
10
Phase 3 Programs
4
Upcoming Catalysts
2
Next Catalyst
Feb 28, 2026
20dMarket Overview
Stock performance and market intelligence
2 upcoming, 0 past
ZL-1102 1% w/w gel BID for 16 weeks Phase 2 Results Expected
Primary completion for ZL-1102 1% w/w gel BID for 16 weeks trial (NCT06380907) in Plaque Psoriasis
SourceZL-1310 Phase 2 Results Expected
Primary completion for ZL-1310 trial (NCT06885281) in Solid Tumors
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
ZL-1310
Solid Tumors
Omadacycline
Community-acquired Bacterial Pneumonia
ZL-1109 (VRDN-003)
Thyroid Eye Disease (TED)
Investigator's Choice of Therapy
Small-cell Lung Cancer
DCC-2618
Gastrointestinal Stromal Tumors
ZL-2306(Niraparib）
Ovarian Cancer
ZL-3101
Eczema
Brivanib 800 mg, QD
Hepatocellular Carcinoma (HCC)
ZL-1102 1% w/w gel BID for 16 weeks
Plaque Psoriasis
Ripretinib
Gastrointestinal Stromal Tumor(GIST)
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
ZL-1310 | Phase 3 | Solid Tumors | - |
Omadacycline | Phase 3 | Community-acquired Bacterial Pneumonia | - |
ZL-1109 (VRDN-003) | Phase 3 | Thyroid Eye Disease (TED) | - |
Investigator's Choice of Therapy | Phase 3 | Small-cell Lung Cancer | - |
DCC-2618 | Phase 2 | Gastrointestinal Stromal Tumors | - |
ZL-2306(Niraparib） | Phase 2 | Ovarian Cancer | - |
ZL-3101 | Phase 2 | Eczema | - |
Brivanib 800 mg, QD | Phase 2 | Hepatocellular Carcinoma (HCC) | - |
ZL-1102 1% w/w gel BID for 16 weeks | Phase 2 | Plaque Psoriasis | - |
Ripretinib | Phase 2 | Gastrointestinal Stromal Tumor(GIST) | - |
Regulatory & News
Approvals, filings, and latest developments